Original Articles
Meng Li, Liwen Zhao, Tao Zhang, Yue Shu, Zhonggui He, Yan Ma, Dan Liu, Yongjun Wang. Redox-sensitive prodrug nanoassemblies based on linoleic acid-modified docetaxel to resist breast cancers[J]. Acta Pharmaceutica Sinica B, 2019, 9(2): 421-432

Redox-sensitive prodrug nanoassemblies based on linoleic acid-modified docetaxel to resist breast cancers
Meng Lia, Liwen Zhaoa, Tao Zhanga, Yue Shua, Zhonggui Hea, Yan Mac, Dan Liub, Yongjun Wanga
a Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China;
b Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China;
c School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
Prodrug nanoassemblies, which can refrain from large excipients, achieve higher drug loading and control drug release, have been placed as the priority in drug delivery system. Reasoning that glutathione (GSH) and reactive oxygen species (ROS) are highly upgraded in tumor tissues which makes them attractive targets for drug delivery system, we designed and synthetized a novel prodrug which utilized mono thioether bond as a linker to bridge linoleic acid (LA) and docetaxel (DTX). This mono thioether-linked conjugates (DTX-S-LA) could self-assemble into nanoparticles without the aid of much excipients. The mono thioether endowed the nanoparticles redox sensitivity resulting in specific release at the tumor tissue. Our studies demonstrated that the nanoassemblies had uniform particle size, high stability and fast release behavior. DTX-S-LA nanoassemblies outperformed DTX solution in pharmacokinetic profiles for it had longer circulation time and higher area under curve (AUC). Compared with DTX solution, the redox dual-responsive nanoassemblies had comparable cytotoxic activity. Besides, the antitumor efficacy was evaluated in mice bearing 4T1 xenograft. It turned out this nanoassemblies could enhance anticancer efficacy by increasing the dose because of higher tolerance. Overall, these results indicated that the redox sensitivity nanoassemblies may have a great potential to cancer therapy.
Key words:    Docetaxel    Nanoassemblies    Mono thioether bond    Linoleic acid    Pharmacokinetics    Antitumor efficacy   
Received: 2018-05-21     Revised: 2018-07-12
DOI: 10.1016/j.apsb.2018.08.008
Funds: This work was supported by Liaoning BaiQianWan Talents Program (No.2016921064,China) and Nature Science Foundation of Guangdong Province (No.2016A020217017,China).
Corresponding author: Dan Liu, Yongjun Wang     Email:sammyld@163.com;wangyongjun@syphu.edu.cn
Author description:
PDF(KB) Free
Meng Li
Liwen Zhao
Tao Zhang
Yue Shu
Zhonggui He
Yan Ma
Dan Liu
Yongjun Wang

1. Ehrlichova M, Vaclavikova R, Ojima I, Pepe A, Kuznetsova LV, Chen J, et al. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells. Naunyn Schmiedebergs Arch Pharmacol 2005;372:95-105.
2. Ye T, Xu W, Shi T, Yang R, Yang X, Wang S, et al. Targeted delivery of docetaxel to the metastatic lymph nodes:a comparison study between nanoliposomes and activated carbon nanoparticles. Asian J Pharm Sci 2015;10:64-72.
3. Zhang H, Wang K, Zhang P, He W, Song A, Luan Y. Redox-sensitive micelles assembled from amphiphilic mPEG-PCL-SS-DTX conjugates for the delivery of docetaxel. Colloids Surf B Biointerfaces 2016;142:89-97.
4. Chu C, Xu P, Zhao H, Chen Q, Chen D, Hu H, et al. Effect of surface ligand density on cytotoxicity and pharmacokinetic profile of docetaxel loaded liposomes. Asian J Pharm Sci 2016;11:655-61.
5. Kim SB, Kok YT, Thuan TV, Chao TY, Shen ZZ. Safety results of docetaxel-(taxotere(R))-based chemotherapy in early breast cancer patients of Asia-Pacific region:Asia-Pacific breast initiative Ⅱ. J Breast Cancer 2015;18:356-64.
6. Seguin C, Kovacevich N, Voutsadakis IA. Docetaxel-associated myalgia-arthralgia syndrome in patients with breast cancer. Breast Cancer 2017;9:39-44.
7. Logie J, Ganesh AN, Aman AM, Al-Awar RS, Shoichet MS. Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model. Biomaterials 2017;123:39-47.
8. Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol 2015;88:20150207.
9. Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev 2013;65:1880-95.
10. Seeta Rama Raju G, Benton L, Pavitra E, Yu JS. Multifunctional nanoparticles:recent progress in cancer therapeutics. Chem Commun (Camb) 2015;51:13248-59.
11. Lin J, Pan Z, Song L, Zhang Y, Li Y, Hou Z, et al. Design and in vitro evaluation of self-assembled indometacin prodrug nanoparticles for sustained/controlled release and reduced normal cell toxicity. Appl Surf Sci 2017;425:674-81.
12. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science 2006;311:622-7.
13. da Silva Santos S, Igne Ferreira E, Giarolla J. Dendrimer prodrugs. Molecules 2016:21.
14. Luo C, Sun J, Sun B, He Z. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy. Trends Pharmacol Sci 2014;35:556-66.
15. Ren G, Jiang M, Xue P, Wang J, Wang Y, Chen B, et al. A unique highly hydrophobic anticancer prodrug self-assembled nanomedicine for cancer therapy. Nanomedicine 2016;12:2273-82.
16. Ge Y, Ma Y, Li L. The application of prodrug-based nano-drug delivery strategy in cancer combination therapy. Colloids Surf B Biointerfaces 2016;146:482-9.
17. Chowdhury P, Nagesh PK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, et al. Development of polyvinylpyrrolidone/paclitaxel selfassemblies for breast cancer. Acta Pharm Sin B 2018;8:602-14.
18. Sun B, Luo C, Cui W, Sun J, He Z. Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy. J Control Release 2017;264:145-59.
19. Luo C, Sun J, Liu D, Sun B, Miao L, Musetti S, et al. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioetherbridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett 2016;16:5401-8.
20. Zock PL, Katan MB. Linoleic acid intake and cancer risk:a review and meta-analysis. Am J Clin Nutr 1998;68:142-53.
21. Bocca C, Bozzo F, Cannito S, Colombatto S, Miglietta A. CLA reduces breast cancer cell growth and invasion through ERα and PI3K/Akt pathways. Chem Biol Interact 2010;183:187-93.
22. Llor X. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin Nutr 2003;22:71-9.
23. Menéndez JA, del Mar Barbacid M, Montero S, Sevilla E, Escrich E, Solanas M, et al. Effect of γ-linolenic acid and oleic acid on paclitaxel cttotoxicity in human breast cells. Eur J Cancer 2001;37:402-13.
24. Bae WK, Park MS, Lee JH, Hwang JE, Shim HJ, Cho SH, et al. Docetaxel-loaded thermoresponsive conjugated linoleic acidincorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer. Biomaterials 2013;34:1433-41.
25. Zhong T, Yao X, Zhang S, Guo Y, Duan XC, Ren W, et al. A selfassembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic. Sci Rep 2016;6:36614.
26. Sun B, Luo C, Yu H, Zhang X, Chen Q, Yang W, et al. Disulfide bond-driven oxidation-and reduction-responsive prodrug nanoassemblies for cancer therapy. Nano Lett 2018;18:3643-50.
27. Xue P, Liu D, Wang J, Zhang N, Zhou J, Li L, et al. Redox-sensitive citronellol-cabazitaxel conjugate:maintained in vitro cytotoxicity and self-assembled as multifunctional nanomedicine. Bioconjug Chem 2016;27:1360-72.
28. Zhang S, Guan J, Sun M, Zhang D, Zhang H, Sun B, et al. Selfdelivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy. Drug Deliv 2017;24:1460-9.
29. Wang J, Sun X, Mao W, Sun W, Tang J, Sui M, et al. Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy. Adv Mater 2013;25:3670-6.
30. Wang Y, Liu D, Zheng Q, Zhao Q, Zhang H, Ma Y, et al. Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into selfassembled nanomedicines. Nano Lett 2014;14:5577-83.
31. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles. Clin Pharmacokinet 2003;42:665-85.
32. Hennenfent KL, Govindan R. Novel formulations of taxanes:a review. Old wine in a new bottle?. Ann Oncol 2006;17:735-49.